Used as a potent antifungal agent, particularly effective against a broad spectrum of fungal pathogens including Aspergillus and Candida species. It functions by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes, through the blockade of lanosterol 14α-demethylase (CYP51). This disruption leads to increased membrane permeability and fungal cell death. The compound exhibits strong tissue penetration and prolonged half-life, making it suitable for systemic treatment of invasive fungal infections. It is primarily developed for intravenous or oral administration in clinical settings for immunocompromised patients, such as those undergoing chemotherapy or organ transplantation. Its trifluoromethoxy and triazole groups enhance metabolic stability and antifungal potency, while the cyclopropylmethoxy moiety contributes to improved pharmacokinetic properties.